Display Settings:

Format

Send to:

Choose Destination

    Br J Clin Pharmacol. 1985 Mar;19(3):373-8.

    Oxaprozin pharmacokinetics in the elderly.

    Greenblatt DJ, Matlis R, Scavone JM, Blyden GT, Harmatz JS, Shader RI.

    A series of 42 healthy male and female volunteers aged 21 to 89 years received a single 1200 mg oral dose of oxaprozin. Kinetics were determined from multiple plasma oxaprozin concentrations measured by h.p.l.c. during 14 days after the dose. Peak plasma oxaprozin concentrations were reached between 3 and 6 h after dosage the majority of subjects, probably reflecting slow absorption from the gastrointestinal tract. Elimination also was slow with a mean half-life of 59 h (range 36 to 92 h). Owing in part to extensive protein binding (mean free fraction 0.0023%), oxaprozin distribution was limited, with apparent volume of distribution averaging 0.25 l/kg. Apparent volume of distribution declined with increasing age, probably reflecting the reduction in lean mass relative to total weight that occurs in the elderly. Total apparent oxaprozin clearance declined with age in men (r = -0.58, P less than 0.01), but was not significantly related to age in women (r = -0.25, NS). This is consistent with the previously described gender-specific reduction in hepatic oxidizing capacity association with increasing age. Thus oxaprozin is a slowly eliminated nonsteroidal anti-inflammatory agent that should be suitable for once daily or every other day administration.

    PMID: 3986088 [PubMed - indexed for MEDLINE]

    PMCID: 1463728

    Supplemental Content

    Click here to read Click here to read Click here to read

    Patient drug information

    • Oxaprozin (Daypro®)

      Oxaprozin is used to relieve pain, tenderness, swelling, and stiffness caused by osteoarthritis (arthritis caused by a breakdown of the lining of the joints) and rheumatoid arthritis (arthritis caused by swelling of the ...